Rationale of decreasing low-density lipoprotein cholesterol below 70 mg/dL in patients with coronary artery disease: A retrospective virtual histology-intravascular ultrasound study by Seo, Young Hoon et al.
Address for correspondence: Jang-Ho Bae, MD, PhD, Division of Cardiology, Heart Center, Konyang University  
Hospital 158, Gwanjeodong-Ro, Seo-Gu, Daejeon, South Korea, 35365, tel: 82-42-600-9400, fax: 82-42-600-9420,  
e-mail: janghobae@yahoo.co.kr
Received: 27.09.2017 Accepted: 25.12.2017
Rationale of decreasing low-density lipoprotein 
cholesterol below 70 mg/dL in patients with  
coronary artery disease: A retrospective virtual 
histology-intravascular ultrasound study
Young Hoon Seo, Duck-Jun Seo, In Geol Song, Ki-Hong Kim,  
Taek-Geun Kwon, Jang-Ho Bae
Division of Cardiology, Heart Center, Konyang University Hospital, Daejeon, South Korea
Abstract
Background: The associations between statin and coronary plaque compositional changes were re-
ported according to the use of high dose or not. An evaluation of the impact of low-density lipoprotein 
cholesterol (LDL-C) < 70 mg/dL by using real world dosages of statin on coronary plaque composition 
was undertaken.
Methods: The study subjects consisted of 61 patients (mean 59.9 years old, 45 males) who underwent 
percutaneous coronary intervention, baseline and follow-up (F/U; mean 8.4 months) virtual histology-
-intravascular ultrasound (VH-IVUS) examination. Change of plaque composition at peri-stent area, 
which was selected in order to measure the identical site at F/U study, was compared according to the 
F/U LDL-C level.
Results: Body mass index, prevalence of dyslipidemia, baseline total cholesterol and baseline LDL-C 
were significantly lower in F/U LDL-C < 70 mg/dL group (14 segments in 10 patients) than F/U LDL-C  
≥ 70 mg/dL group (79 segments in 51 patients). F/U high-density lipoprotein cholesterol (HDL-C,  
OR 1.06, 95% CI 1.00–1.11, p = 0.054) and F/U LDL-C < 70 mg/dL (OR 3.43, 95% CI 0.97–12.17,  
p = 0.056) showed strong tendency of regression of necrotic core volume (NCV) ≥ 10%. In multivariable logis-
tic regression analysis, F/U HDL-C (OR 1.07, 95% CI 1.01–1.14, p = 0.020) and F/U LDL-C < 70 mg/dL  
(OR 8.02, 95% CI 1.58–40.68, p = 0.012) were the independent factors for regression of NCV ≥ 10%. 
Conclusions: Follow-up LDL-C level < 70 mg/dL with any types of statins and increase of HDL-C 
were associated with regression of NCV ≥ 10% in patients with coronary artery disease. (Cardiol J 2018; 
25, 6: 674–682)
Key words: cholesterol, LDL, coronary artery disease, intravascular ultrasonography, 
myocardial ischemia, coronary stenosis
Introduction
According to the National Cholesterol Educa-
tion Program-Adult Treatment Panel-III (NCEP-
-ATP-III), target level of low-density lipoprotein 
cholesterol (LDL-C) in patient with coronary 
disease or coronary heart disease risk equivalents 
is less than 100 mg/dL [1]. But accumulating data, 
since NCEP-ATP-III was reported, supports lower 
LDL-C which can result in better outcomes [2, 3], 
and guidelines on treatment of cholesterol in pa-
tients with high cardiovascular risk recommends 
more intensive lipid-lowering therapy, LDL-C less 
than 70 mg/dL [4, 5].
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Statin is a very important in coronary artery 
disease (CAD) in terms of coronary plaque re-
gression as well as its own lipid lowering effect. 
High dose statin such as atorvastatin 80 mg or 
rosuvastatin 40 mg decreased coronary plaque 
volume in follow-up (F/U) intravascular ultrasound 
(IVUS) studies [2, 6]. Recent studies using virtual 
histology (VH)-IVUS showed that statin therapy 
draws a favorable coronary plaque modification 
such as decreased necrotic core volume (NCV) as 
well as decreased total plaque volume in patients 
with CAD [7, 8]. However, it was very difficult to 
compare the exact lesion site when F/U VH-IVUS 
study is done, even when a specific landmark such 
as branching point and/or perivascular marking was 
used. Furthermore, VH-IVUS captures the scanned 
frames at the end-diastolic point and this is another 
difficult reason why F/U VH-IVUS cannot exactly 
capture the same lesion frame with the F/U study.
Till now, associations between statin and coro-
nary plaque compositional changes were reported 
according to the use of high dose or not. Therefore, 
the present study sought to evaluate the impact of 
LDL-C < 70 mg/dL by using any practical dosage 
of statin on coronary plaque composition, especially 
the necrotic core which is a key feature of vulner-
able plaque, and the peri-stent coronary plaque for 
measuring the identical site was selected when 
doing the F/U VH-IVUS study.
Methods
Subjects
Among 298 consecutive patients who under-
went percutaneous coronary intervention (PCI) 
and VH-IVUS for CAD in Heart Center, Konyang 
University Hospital, 72 patients  underwent F/U 
coronary angiography (CAG) and VH-IVUS at 
mean 8.4 ± 1.4 months were included. There was 
no cardiogenic shock or need for intra-aortic bal-
loon pump during the procedure and there were 
no major cardiovascular events, such as stroke, 
myocardial infarction or death. Eleven patients who 
could not take the statin because of side effects or 
those who showed unavailable lipid level were also 
excluded. In order to exactly compare the same 
segment of coronary plaque with F/U VH-IVUS 
examination, the proximal and distal segment of 
the implanted stent was used for the analysis. If 
the reference proximal and distal segment were in 
the side branch or had no plaque, those segments 
were excluded from the analysis. Finally, a total of 
93 segments of 61 patients were enrolled in this 
study, specifically 49 proximal segments and 
44 distal segments.
Clinical information including past medical 
history or medication history of patients were 
obtained by medical records or from patients and 
their relatives. Informed consent was obtained 
from each patient. Biochemical laboratory find-
ings were obtained at least 8 h after fasting state 
at times of the index procedure and F/U proce-
dure. In cases of primary PCI, fasting blood was 
obtained the following morning. Coronary risk 
factors included hypertension (blood pressure 
≥ 140/90 mmHg based on the average of repeated 
readings or patients on antihypertensive drugs), 
dyslipidemia (total cholesterol [TC] > 200 mg/dL 
and/or triglyceride > 150 mg/dL and/or LDL-C 
> 130 mg/dL or patients on lipid lowering therapy), 
diabetes mellitus (controlled diet, oral hypogly-
cemic agents, or insulin; or fasting glucose level 
≥ 126 mg/dL or 2 h oral glucose tolerance test 
≥ 200 mg/dL) and current cigarette smoking.
Subjects received standardized treatment 
including one conventional dose of statin (atorv-
astatin 10 mg or rosuvastatin 10 mg or pitavastatin 
2 mg) during the F/U period and no unnecessary 
procedures were performed. All study subjects re-
ceived similar intensity of general advice for medi-
cation, diet, exercise and cessation of smoking. 
This study was approved by the ethics committee 
of Konyang University Hospital (2016-08-024) and 
was in accordance with the Declaration of Helsinki.
IVUS examination and analysis
Baseline and F/U VH-IVUS examination were 
performed during CAG after intracoronary admin-
istration of 100–200 mg nitroglycerin using with 
dedicated 20-MHz, 2.9 F monorail, electronic 
Eagle Eye Gold IVUS catheter (Volcano Thera-
peutics, Rancho Cordova, California) and VH-IVUS 
console (Volcano Therapeutics, Rancho Cordova, 
California). The IVUS catheter was advanced into 
the target lesion after wiring or ballooning and 
automatic pullback at 0.5 mm/s. The VH-IVUS 
image was recorded on DVD-ROM for subsequent 
off-line analysis.
Both qualitative and quantitative analyses of 
gray scale IVUS images were performed according 
to criteria of the American College of Cardiology’s 
Clinical Expert Consensus Document on IVUS [9]. 
External elastic membrane (EEM) and cross-
sectional area (CSA) was measured with custom-
ized software (IVUS Lab., Volcano Therapeutics, 
Rancho Cordova, CA, USA). The remodeling index 
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was calculated as the lesion EEM CSA divided by 
the average reference EEM CSA.
In this study, characteristics of culprit lesion 
were measured before PCI,  the lesion but also 
proximal and distal reference segment to the stent 
after PCI were examined. The usual imaging stud-
ies comparing plaque composition with the F/U 
study which uses the side branch, vessel calcium, 
curvature, etc. However, it is very difficult to 
select the same segment of the F/U imaging with 
the baseline segment. So, the proximal and distal 
segment of the implanted stent was selected. F/U 
CAG and VH-IVUS examination was performed for 
comparison in same manner.
Spectral analysis of IVUS  
radiofrequency data
These analyses were done on the target lesion 
with customized software (IVUS Lab., Volcano 
Therapeutics, Rancho Cordova, CA, USA). For both 
lumen and media-adventitia interface, automatic 
border detection was done at the predefined lesion 
segment. Then, the border detection was manually 
corrected again in the lesion after automatic bor-
der detection. Manual analyzing of the image was 
performed by two cardiologists who were unaware 
of subject lipid profile, and third cardiologist, who 
was also blinded to lipid profile intervened when an 
opinion differed. After confirming border detection, 
the software automatically calculates and shows 
the results. For each frame, histologic findings 
were expressed in colors (green for fibrous, green-
yellow for fibro-fatty, white for dense calcified, and 
red for necrotic core area). The area of each plaque 
component was analyzed at the minimal luminal 
area site and plaque volume over the culprit lesion 
as well as the reference segments which were used 
for comparison according to F/U examination at the 
proximal and the distal segment to the implanted 
stent (Fig. 1).
Figure 1. Virtual histology-intravascular ultrasound (VH-IVUS) findings of the analyzed segment in patient. Baseline 
and 7-months follow-up (FU) VH-IVUS images of the reference segment proximal to the stent in 73-year-old male. 
Images showed that necrotic core (NC) volume was decreased from 14% to 3% and NC area at minimal luminal area 
was also decreased from 27% to 8% whereas fibrofatty (FF) volume was increased from 16% to 27% and FF area was 
increased from 13% to 26%. He had atorvastatin daily 10 mg for 7-months FU period. Patient baseline low-density 
lipoprotein cholesterol level was decreased from 98 mg/dL to 68 mg/dL at 7-month FU period.
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Statistical analysis
All analyses were performed with SPSS (ver-
sion 18.0; SPSS Inc., Chicago, Illinois). Continuous 
variables were analyzed using the Student t-test 
or Mann-Whitney test and categorical data were 
compared by c2 test or Fisher exact test. Com-
parison between the three groups was performed 
using analysis of variance or Kruskal-Wallis test. 
Univariate binary logistic regression analysis was 
done to see the relationship between regression 
of NCV ≥ 10% and F/U lipid level. Criteria of F/U 
lipid level were chosen based on established value 
in the guidelines. Multivariable logistic regression 
analysis was done to find independent factors for 
regression of NCV ≥ 10%. All factors revealing 
p-value < 0.1 in baseline findings and univari-
ate analysis were entered into the multivariable 
analysis as variables. Dyslipidemia and baseline TC 
were not co-entered into the multivariable analysis 
because of its overlapping definition. A p-value 
< 0.05 was considered statistically significant.
Results
Patient demographics
Follow-up LDL-C level < 70 mg/dL was 
achieved in 10 patients (Group 1, mean F/U LDL-C 
56.9 ± 16.8 mg/dL) out of 61 patients and the re-
maining 51 patients showed F/U LDL-C ≥ 70 mg/dL 
(Group 2, mean F/U LDL-C 96.3 ± 23.6 mg/dL). 
Table 1 showed that group 1 had a lower body 
mass index (23.4 ± 2.9 vs. 26.3 ± 3.7, p = 0.021), 
lower prevalence of dyslipidemia (10% vs. 48%, 
p = 0.035), lower level of baseline TC (168.1 ± 
± 41.5 mg/dL vs. 195.8 ± 35.8 mg/dL, p = 0.033) and 
lower level of baseline LDL-C (105.1 ± 26.3 mg/dL 
vs. 130.0 ± 28.7 mg/dL, p = 0.014) compared to the 
group 2. F/U lipid values also showed similar sig-
nificant differences between the two groups. But, 
changes of each lipid value during the F/U period 
showed no significant differences between the two 
groups. Other demographics such as kind of statin, 
medications, ejection fraction (EF) and diagnosis 
revealed no significant differences between the two 
groups. Angiographic and VH-IVUS findings of the 
culprit lesion (n = 61), which was a stented lesion 
and was not used for comparison between baseline 
and F/U examination, also showed no significant 
differences between the two groups (Table 2).
Coronary plaque composition according  
to the LDL-C level
When the plaque composition of analyzed seg-
ments between the two groups according to the F/U 
LDL-C level < 70 mg/dL was compared, there were 
no significant differences in terms of baseline and 
F/U plaque composition (Table 3). The changes of 
plaque composition were not significantly different 
between the two groups during the F/U period. 
There were also no significant differences in seg-
ment length, plaque burden and imaged vessel of 
analyzed segments.
However, as shown in Table 4, F/U high-
-density lipoprotein cholesterol (HDL-C) (odds 
ratio [OR] 1.06, 95% confidence interval [CI] 
1.00–1.11, p = 0.054) and F/U LDL-C < 70 mg/dL 
(OR 3.43, 95% CI 0.97–12.17, p = 0.056) showed 
a strong tendency of regression of NCV ≥ 10%. 
Multivariable logistic regression analysis with 
variables of BMI, baseline TC, baseline LDL-C, 
EF, remodeling index, stent length, F/U HDL-C 
and F/U LDL-C < 70 mg/dL was performed to 
find independent factors for regression of NCV 
≥ 10%. F/U HDL-C (OR 1.07, 95% CI 1.01– 
–1.14, p = 0.020) and F/U LDL-C < 70 mg/dL 
(OR 8.02, 95% CI 1.58–40.68, p = 0.012) were 
the independent factors for regression of NCV 
≥ 10% and other variables did not show statistical 
significance in multivariable analysis (Table 5). Coro-
nary plaque compositional changes according to statin 
type used show no significant differences (Table 6).
Discussion
Necrotic core, one of the coronary plaque com-
positions, is a most important feature of vulnerable 
plaque. It is associated with no-reflow phenomenon 
during PCI [10], positive coronary artery remod-
eling [11], clinical presentation feature such as 
acute coronary syndrome [12], high strain site [13] 
and localized endothelial dysfunction [14]. All of the 
above features are associated with worse clinical 
presentation or prognosis in patients with CAD. 
Necrotic core of more than 10% of coronary plaque 
composition is an important factor in determining 
coronary lesion classification such as thin-cap fi-
broatheroma, fibrotic plaque, fibrocalcific atheroma 
and pathological intimal thickening [15].
The main finding of this study was that the tar-
get level of LDL-C < 70 mg/dL is very important in 
regression of percent NCV ≥ 10% in patients with 
CAD. And this study also showed other significant 
findings as follows: 1) Decreasing the LDL-C level 
under 70 mg/dL was more important than increas-
ing the HDL-C level for reducing NCV more than 
10%; 2) Coronary plaque compositional changes 
showed no significant differences among the statin 
types in conventional dosage.
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Table 1. Baseline clinical characteristics of the patients.
Variables Total  
(n = 61)
Group 1 (n = 10) F/U 
LDL-C < 70 mg/dL
Group 2 (n = 51) F/U 
LDL-C ≥ 70 mg/dL
P
Age [years] 59.9 ± 11.4 60.1 ± 9.2 60.0 ± 11.9 0.972
Male gender 45 (73.8%) 8 (80.0%) 37 (72.5%) 1.000
Weight [kg] 68.9 ± 11.9 65.4 ± 11.9 69.6 ± 11.9 0.321
BMI [kg/m2] 25.8 ± 3.7 23.4 ± 2.9 26.3 ± 3.7 0.021
Smoking 30 (49.2%) 7 (70.0%) 23 (45.1%) 0.182
Comorbidities:
Hypertension 34 (55.7%) 5 (50.0%) 29 (56.9%) 0.738
DM 15 (24.6%) 3 (30.0%) 12 (23.5%) 0.696
History of MI 0 (0%) 0 (0%) 0 (0%)
Dyslipidemia 25 (41.7%) 1 (10.0%) 24 (47.1%) 0.035
Baseline lipid level [mg/dL]:
TC 191.3 ± 37.9 168.1 ± 41.5 195.8 ± 35.8 0.033
TG 164.9 ± 102.1 211.9 ± 177.0 154.5 ± 79.0 0.351*
HDL-C 43.3 ± 9.3 39.0 ± 7.1 44.2 ± 9.5 0.107
LDL-C 125.7 ± 29.6 105.1 ± 26.3 130.0 ± 28.7 0.014
F/U lipid level [mg/dL]:
TC 150.7 ± 34.3 113.6 ± 20.3 158.2 ± 31.6 < 0.001
TG 154.2 ± 86.8 161.8 ± 121.9 152.7 ± 79.7 0.764
HDL-C 44.9 ± 10.5 42.9 ± 9.93 45.3 ± 10.7 0.530
LDL-C 89.9 ± 26.9 56.9 ± 16.8 96.3 ± 23.6 < 0.001*
Changes of lipid level [mg/dL]:
DTC –41.4 ± 45.2 –54.5 ± 30.5 –38.8 ± 47.4 0.377*
DTG –11.5 ± 95.3 –50.1 ± 131.2 –3.8 ± 86.1 0.346*
DHDL-C 1.5 ± 10.5 4.0 ± 13.2 1.0 ± 10.0 0.413
DLDL-C –34.8 ± 30.8 –41.2 ± 22.7 –33.5 ± 32.2 0.477
Medication: 1.000
ACEI 46 (75.4%) 8 (80.0%) 38 (74.5%) 1.000
ARB 7 (11.5%) 1 (10.0%) 6 (11.8%) 0.147
BB 39 (63.9%) 4 (40.0%) 35 (68.6%) 1.000
CCB 9 (14.8%) 1 (10.0%) 8 (15.7%) 1.000
ASA 58 (95.1%) 10 (100.0%) 48 (94.1%) 1.000
Insulin 1 (1.6%) 0 (%) 1 (2.0%) 1.000
OHA 12 (19.7%) 2 (20.0%) 10 (19.6%) 0.322
Lipid lowering agent 54 (88.5%) 8 (80.0%) 46 (90.2%) 0.082
EF [%] 63.7 ± 8.7 68.1 ± 6.0 62.9 ± 8.9 0.678
Diagnosis: 28/7/6/20 5/2/0/3 23/5/6/17 0.203
SAP/UA/ 
/NSTEMI/STEMI
(45.9%/11.5%/ 
/9.8%/32.8%)
 (50.0%/20.0%/ 
/0/80.0%)
(45.1%/9.8%/ 
/11.8%/33.3%)
Prescribed statin:
Atorvastatin 31 (50.8%) 5 (50.0%) 26 (51.0%)
Rosuvastatin 13 (21.3%) 4 (40.0%) 9 (17.6%)
Pitavastatin 17 (27.9%) 1 (10.0%) 16 (31.4%)
*Mann-Whitney test; n — number; F/U — follow-up; LDL-C — low-density lipoprotein cholesterol; BMI — body mass index; DM — diabetes 
mellitus; MI — myocardial infarction; TC — total cholesterol; TG — triglyceride; HDL-C — high-density lipoprotein cholesterol; ACE — angio-
tensin converting enzyme inhibitor; ARB — angiotensin receptor blocker; BB — beta-blocker; CCB — calcium channel blocker; ASA — acetyl-
salicylic acid; OHA — oral hypoglycemic agent; EF — ejection fraction; SAP — stable angina pectoris; UA — unstable angina; NSTEMI — non 
ST-segment elevation myocardial infarction; STEMI — ST-segment elevation myocardial infarction
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Table 3. Comparison of baseline and follow-up (F/U) virtual histology-intravascular ultrasound findings  
of analyzed segment.
Variables Total  
(n = 93)
Group 1 (n = 14) F/U
LDL-C < 70 mg/dL
Group 2 (n = 79) F/U
LDL-C ≥ 70 mg/dL
P
Analyzed segment: 0.511
Proximal to the stent 17 (18.3%) 3 (21.4%) 14 (17.7%)
Distal to the stent 12 (12.9%) 3 (21.4%) 9 (11.4%)
Both side 64 (68.8%) 8 (57.1%) 56 (70.9%)
Segment length [mm] 5.1 ± 2.2 5.8 ± 2.4 5.0 ± 2.1 0.175
Plaque burden [%] 50.1 ± 10.1 49.2 ± 12.4 50.23 ± 9.69 0.731
Imaged vessel 54/11/25/3 11/0/2/1 43/11/23/2 0.154
 LAD/LCX/ 
/RCA/LM
(58%/12%/ 
/275/35)
(79%/0%/ 
/14%/7%)
(54%/14%/ 
/29%/3%)
Baseline
Fibrous volume [mm3] 10.9 ± 9.4 11.8 ± 13.0 10.7 ± 8.7 0.419*
Fibrofatty volume [mm3] 2.7 ± 3.5 3.2 ± 5.0 2.6 ± 3.2 0.444*
Dense calcium volume [mm3] 1.3 ± 1.6 1.5 ± 2.3 1.3 ± 1.5 0.440*
Necrotic core volume [mm3] 2.7 ± 3.2 3.3 ± 4.4 2.6 ± 3.0 0.364*
Fibrous volume [%] 62.1 ± 11.2 61.6 ± 9.4 62.2 ± 11.5 0.856
Fibrofatty volume [%] 14.3 ± 10.2 14.5 ± 9.4 14.2 ± 10.4 0.924
Dense calcium volume [%] 8.4 ± 8.3 7.9 ± 5.3 8.5 ± 8.7 0.827
Necrotic core volume [%] 15.0 ± 10.2 16.1 ± 9.7 14.8 ± 10.3 0.677
F/U:
Fibrous volume [mm3] 10.8 ± 9.6 12.8 ± 14.0 10.5 ± 8.7 0.427*
Fibrofatty volume [mm3] 2.5 ± 2.5 2.8 ± 1.9 2.4 ± 2.6 0.083*
Dense calcium volume [mm3] 1.5 ± 2.2 2.0 ± 3.8 1.4 ± 1.8 0.221*
Necrotic core volume [mm3] 2.7 ± 3.8 3.8 ± 7.8 2.5 ± 2.6 0.198*
Fibrous volume  [%] 61.5 ± 12.8 62.1 ± 9.5 61.3 ± 13.3 0.845
Fibrofatty volume  [%] 15.3 ± 11.0 21.2 ± 15.1 14.2 ± 9.9 0.115
Dense calcium volume  [%] 10.1 ± 13.0 6.1 ± 6.4 10.8 ± 13.7 0.219
Necrotic core volume  [%] 13.9 ± 9.5 10.7 ± 8.7 14.5 ± 9.5 0.174
Table 2. Angiographic and virtual histology-intravascular ultrasound findings of culprit lesions.
Variables Total  
(n = 61)
Group 1 (n = 10) F/U 
LDL-C < 70 mg/dL
Group 2 (n = 51) F/U 
LDL-C ≥ 70 mg/dL
P
Lesion length [mm] 19.5 ± 7.8 18.6 ± 7.6 19.7 ± 7.9 0.678
Plaque volume [mm3] 26.0 ± 21.5 42.1 ± 29.7 35.0 ± 19.8 0.256
Remodeling index 1.00 ± 0.19 1.11 ± 0.25 0.98 ± 0.17 0.052
Lesion characteristics [%]:
Fibrous area 58.6 ± 14.1 62.5 ± 9.5 57.8 ± 14.8 0.337
Fibrofatty area 13.9 ± 12.2 12.9 ± 9.2 14.1 ± 12.7 0.691*
Dense-calcium area 8.7 ± 10.4 6.3 ± 4.6 9.2 ± 11.2 0.424
Necrotic core area 19.1 ± 11.0 19.4 ± 8.8 19.0 ± 11.4 0.903
Kinds of stents: 52/13/5/23 8/4/0/2 44/9/5/21 0.328
Cypher/Taxus/ 
/Endeavor/Pico
(55.9%/14.0%/ 
/5.4%/24.7%)
(57.1%/28.6%/ 
/0%/14.3%)
(55.7%/11.4%/ 
/6.3%/26.6%)
Stent length [mm] 22.4 ± 4.6 20.4 ± 2.8 22.7 ± 4.7 0.082
Stent diameter [mm] 3.3 ± 0.4 3.1 ± 0.3 3.3 ± 0.4 0.210
*Mann-Whitney test; n — number, F/U — follow-up, LDL-C — low-density lipoprotein cholesterol
Æ
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Table 6. Change of virtual histology-intravascular ultrasound findings according to the statins.
Variables Atorvastatin  
(n = 49)
Rosuvastatin  
(n = 19)
Pitavastatin  
(n = 25)
P
Change of plaque composition [mm3]:
Fibrous volume 0.7 ± 3.4 –1.0 ± 3.0 –0.9 ± 4.8 0.346*
Fibrofatty volume 0.0 ± 3.2 –0.6 ± 2.8 –0.3 ± 1.9 0.700*
Dense calcium volume 0.1 ± 1.2 0.5 ± 2.2 0.3 ± 1.1 0.467*
Necrotic core volume 0.0 ± 2.5 –0.3 ± 2.7 0.0 ± 2.6 0.161*
Change of % plaque composition [%]:
Fibrous volume –0.4 ± 13.4 1.1 ± 7.6 –2.4 ± 8.2 0.576
Fibrofatty volume 2.3 ± 14.4 –0.2 ± 10.6 –0.7 ± 7.5 0.712*
Dense calcium volume 0.6 ± 8.4 0.9 ± 7.8 4.4 ± 13.2 0.437*
Necrotic core volume –2.0 ± 10.2 –2.0 ± 9.4 1.2 ± 7.4 0.362
*Kruskal-Wallis test; n — number
Table 5. Independent factors for regression  
of percent necrotic core volume using multi-
variable logistic regression analysis.
Variables OR 95% CI P
Body mass index N/S
Baseline TC N/S
Baseline LDL-C N/S
Ejection fraction N/S
Remodeling index N/S
Stent length N/S
F/U HDL-C 1.07 1.01–1.14 0.020
F/U LDL-C < 70 mg/dL 8.02 1.58–40.68 0.012
Abbreviations — see Table 4
Table 4. Univariate analysis for regression of 
percent necrotic core volume.
Variables OR 95% CI P
F/U TC < 200 mg/dL 1.10 0.12–9.90 0.933
F/U TG < 150 mg/dL 0.66 0.22–1.96 0.450
F/U HDL-C [mg/dL] 1.06 1.00–1.11 0.054
F/U LDL-C < 70 mg/dL 3.43 0.97–12.17 0.056
OR — odds ratio; CI — confidence interval; F/U — follow-up;  
TC — total cholesterol; TG — triglyceride; HDL-C — high-density  
lipoprotein cholesterol; LDL-C — low-density lipoprotein cholesterol
Table 3. (cont.). Comparison of baseline and follow-up (F/U) virtual histology-intravascular ultrasound 
findings of analyzed segment.
Variables Total  
(n = 93)
Group 1 (n = 14) F/U
LDL-C < 70 mg/dL
Group 2 (n = 79) F/U
LDL-C ≥ 70 mg/dL
P
Change of plaque composition [mm3]:
Fibrous volume –0.1 ± 3.8 1.0 ± 3.1 –0.3 ± 3.9 0.615*
Fibrofatty volume –0.2 ± 2.8 –0.4 ± 4.4 –0.2 ± 2.5 0.185*
Dense calcium volume 0.2 ± 1.4 0.4 ± 1.7 0.2 ± 1.4 0.410*
Necrotic core volume 0.0 ± 2.6 1.0 ± 4.0 –0.1 ± 2.4 0.243*
Change of % plaque composition [%]:
Fibrous volume –0.6 ± 11.2 1.0 ± 15.1 –0.8 ± 10.4 0.685
Fibrofatty volume 1.0 ± 12.1 6.7 ± 17.5 0.0 ± 10.7 0.372*
Dense calcium volume 1.7 ± 9.9 –1.8 ± 6.8 2.3 ± 10.2 0.191*
Necrotic core volume –1.1 ± 9.3 –5.4 ± 12.3 –0.4 ± 8.6 0.167
*Mann-Whitney test; n — number; LDL-C — low-density lipoprotein cholesterol; LAD — left anterior descending artery; LCX — left circumflex 
artery; RCA — right coronary artery; LM — left main
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The YELLOW (Reduction in Yellow Plaque 
by Aggressive Lipid-Lowering Therapy) study 
showed that intensive statin therapy was more 
effective in reducing lipid core compared with 
standard statin therapy [16]. And there were many 
other studies showing the relationship between 
statin and plaque composition by using VH-IVUS. 
However, these studies did not show consistent re-
sults. For example, STABLE study [8] compared the 
effect of moderate intensity rosuvastatin (10 mg) 
with high intensity rosuvastatin (40 mg) on coro-
nary plaque composition and it showed that both 
dosages reduced NCV and plaque volume but 
showed no differences between two groups. On the 
other hand, Matsushita et al. [17] showed moderate 
intensity statin therapy (atorvastatin 20 mg or pita-
vastatin 4 mg) resulted in more favorable outcome 
than low intensity statin therapy (pravastatin 10 mg 
or fluvastatin 30 mg). These inconsistent results 
with statin effects on coronary plaque composition 
could have resulted from different types and dos-
ages of statins.
The other issue in this study was the coronary 
segment for analysis. All other studies analyzed 
the intermediate lesion for study. However, it was 
thought to be a limitation for the F/U study, be-
cause it was sometimes difficult to findan exactly 
identical lesion site with the baseline analyzed 
segment. Furthermore, VH-IVUS capture frames 
at the end-diastole, thus it can cause analysis of 
different frames, even though the examiner defines 
the same segment for F/U examination. This is 
a reason why the proximal or distal segment was 
selected for analysis in this F/U study.
Limitations of the study
This study has several limitations. First, this 
study was single center, retrospective study and 
consisted of small number of subjects. Because of 
the small number of subjects, regardless of same 
medical advice, patient compliance could be dif-
ferent and it might have influenced the results. 
Second, the number of patients with F/U LDL-C 
< 70 mg/dL was small (14 segments in 10 pa-
tients) and their baseline TC and LDL-C levels 
were lower, this may affect the results in this 
study. Third, group 1 had a tendency of positive 
remodeling compared to group 2. This did not, 
however, show statistical significance between the 
two groups. Furthermore, it was an analysis of the 
culprit lesion, not the analyzed segment for the 
F/U examination. And fourth, inaccuracy of detect-
ing the necrotic core by VH-IVUS [18] may have 
presented results showing a decreasing tendency 
of NCV in group 1. However, those tendencies 
were not seen in group 2, so it was thought that 
this change of plaque composition by groups can 
be the F/U LDL-C effects.
This study found that the statin types used in 
conventional dosage were not important in chang-
ing the percent NCV, but the target LDL-C < 70 
mg/dL was important, although it is well known 
that a high dose of stain can draw lower LDL-C 
level and a specific statin can decrease more LDL-C 
than others. This study in line with the previous 
studies suggests that F/U LDL-C is an important 
factor in determining coronary plaque composition 
and the statin type used is not so important. LDL-C 
and HDL-C were important in decreasing the per-
cent NCV and this finding suggests that at least 
LDL-C < 70 mg/dL with any statin is important 
rather than doses or types of statin.
Conclusions
In conclusion, F/U LDL-C level < 70 mg/dL 
with any type of statin is associated with regression 
of NCV ≥ 10% in patients with CAD. This result sup-
ports the rationale of lowering LDL-C < 70 mg/dL 
suggested in several guidelines.
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